{
    "ticker": "ACTU",
    "name": "Actinium Pharmaceuticals, Inc.",
    "description": "Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on advancing targeted therapies for patients with cancer. Founded in 2011, Actinium is pioneering the use of its proprietary Antibody Radiation Conjugate (ARC) technology to develop therapeutics that deliver targeted radiation directly to cancer cells. This innovative approach aims to improve the efficacy of cancer treatments while minimizing damage to surrounding healthy tissue. The company's lead product candidate, Iomab-B, is currently being evaluated in a pivotal Phase 3 clinical trial for use in patients with relapsed or refractory acute myeloid leukemia (AML) prior to a stem cell transplant. Actinium is also developing Iomab-ACT, a targeted conditioning agent intended to improve outcomes in patients undergoing hematopoietic stem cell transplants. With a strong pipeline and a commitment to addressing unmet medical needs in oncology, Actinium's mission is to transform the treatment landscape for patients suffering from blood cancers.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "New York, New York, USA",
    "founded": "2011",
    "website": "https://www.actiniumpharmaceuticals.com",
    "ceo": "Sandesh Seth",
    "social_media": {
        "twitter": "https://twitter.com/ActiniumPharma",
        "linkedin": "https://www.linkedin.com/company/actinium-pharmaceuticals/"
    },
    "investor_relations": "https://investors.actiniumpharmaceuticals.com",
    "key_executives": [
        {
            "name": "Sandesh Seth",
            "position": "CEO"
        },
        {
            "name": "Dr. Dale Ludwig",
            "position": "Chief Scientific Officer"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "Iomab-B",
                "Iomab-ACT"
            ]
        }
    ],
    "seo": {
        "meta_title": "Actinium Pharmaceuticals, Inc. | Targeted Cancer Therapies",
        "meta_description": "Explore Actinium Pharmaceuticals, Inc., a leader in targeted cancer therapies utilizing its proprietary Antibody Radiation Conjugate technology to improve patient outcomes.",
        "keywords": [
            "Actinium Pharmaceuticals",
            "Cancer Treatment",
            "Iomab-B",
            "Iomab-ACT",
            "Blood Cancer",
            "AML",
            "Biopharmaceuticals"
        ]
    },
    "faq": [
        {
            "question": "What does Actinium Pharmaceuticals do?",
            "answer": "Actinium Pharmaceuticals develops targeted therapies for cancer using its proprietary Antibody Radiation Conjugate technology."
        },
        {
            "question": "What are the lead products of Actinium?",
            "answer": "Actinium's lead products are Iomab-B and Iomab-ACT."
        },
        {
            "question": "Where is Actinium headquartered?",
            "answer": "Actinium is headquartered in New York, New York, USA."
        },
        {
            "question": "When was Actinium founded?",
            "answer": "Actinium was founded in 2011."
        },
        {
            "question": "Who is the CEO of Actinium Pharmaceuticals?",
            "answer": "The CEO of Actinium Pharmaceuticals is Sandesh Seth."
        }
    ],
    "competitors": [
        "CLVS",
        "IMAB",
        "EXEL",
        "MGNX"
    ],
    "related_stocks": [
        "BMY",
        "JNJ",
        "PFE",
        "AMGN"
    ]
}